Navigation Links
China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
Date:10/27/2008

BEIJING, Oct. 27 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic products today announced that it will report selected unaudited financial numbers including consolidated revenues, net income and earnings per ADS for the second fiscal quarter ended September 30, 2008 ("2Q FY2008") on November 18, 2008 and full unaudited financial results for 2Q FY2008 together with the preliminary purchase price allocation of the acquisition of HPV-DNA Chip and SPR-based Analysis System (the "Acquisition") on December 18, 2008. The Company's 2008 fiscal year ends on March 31, 2009 ("FY2008").

The Company is working on the valuation of the tangible and intangible assets to be acquired in the Acquisition as required by United States Generally Accepted Accounting Principles and expects to complete the preliminary purchase price allocation in mid-December. The Company has engaged independent valuers to perform a valuation on the assets for the purpose of purchase price allocation. The Company will also provide an estimated annual amortization of the intangible assets together with the preliminary purchase price allocation on December 18, 2008.

The Company has received a number of investor inquiries about its indebtedness and existence of any investment in financial derivatives. As of today, the Company did not have any bank borrowings. The Company's outstanding debts are long term and consist of its US$150 million 3.5% convertible notes due November 15, 2011 and US$276 million 4% convertible notes due August 15, 2013. The convertible note holders do not have right to require early redemption of any of the convertible notes before their respective maturity dates.

The Company maintains its cash with reputable banks in the form of bank balances and short term bank deposits. The Company did not invest in any kind of financial derivatives.

The Company's CEO, Mr. Xiaodong Wu, CFO, Mr. Sam Tsang and CTO, Dr. Zhong Chen will host an earnings conference call at 8:00 a.m., Eastern Time on December 18, 2008 (9:00 p.m. Beijing/Hong Kong time).

Conference Call

The dial-in details for the live conference call are as follows:

-- U.S. Toll Free Number 1-800-510-0178

-- International Dial-in Number 1-617-614-3450

Passcode: CMEDCALL A live webcast of the conference call will be available on http://ir.chinameditech.com .

A replay of this webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. Eastern Time on December 19, 2008. The dial-in details for the replay are as follows:
-- U.S. Toll Free Number 1-888-286-8010

-- International Dial-in Number 1-617-801-6888

Passcode: 58583488

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and system using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

For further information, please contact:

Winnie Yam

Tel: +86-10-6530-8833

Email: IR@chinameditech.com


'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 2017  If only one in every hundred ... resistance to chemotherapy, thousands of cancer cells would ... on finding these mutations in ever-smaller subpopulations of ... DNA in blood — to guide treatment decisions ... Unfortunately, however, detecting these genetic anomalies may be ...
(Date:2/16/2017)... (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power of ... negative breast cancer (TNBC), announced today their completion of the ... The YEi Start in France ... business in France and Europe.  ImMAGE ... an intensive one week immersion in France ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
Breaking Biology Technology:
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
(Date:1/19/2017)... Oregon and PUNE, India , January 19, 2017 ... Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," ... growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... Jan. 18, 2017  In vitro diagnostic (IVD) companies ... and acquisitions (M&A), and Kalorama Information expects that trend ... have been shifting. Generally, uncertainty in reimbursement and healthcare ... U.S. has changed the acquisitions landscape. Instead of looking ... companies buying partners outside of their home country and ...
Breaking Biology News(10 mins):